摘要
目的探讨p53和表皮生长因子受体(Epidermal growth factor receptor,EGFR)在乳腺浸润性导管癌中的表达及其临床病理意义。方法采用免疫组化SP法检测30例正常乳腺组织、160例浸润性乳腺癌组织中p53和EGFR的表达。结果乳腺浸润性导管癌中p53、EGFR的阳性表达与正常乳腺组织间差异有显著统计学意义(P<0.01)。p53、EGFR的阳性表达与浸润性乳腺导管癌的病理分级、临床分期及淋巴结转移有关(P<0.05),而与患者的年龄、肿块的大小无关。结论 p53和EGFR在乳腺浸润性导管癌的发生、发展过程中发挥了一定的作用,两者联合检测有助于预测患者的预后,并为临床进行靶向治疗提供依据。
Objective To study the expression and significance of p53 and EGFR in breast invasive ductal carcinoma tissue.Methods The expression of p53 and EGFR was detected in 30 cases of normal breast tissue and 160 cases of breast invasive ductal carcinoma by using immunohistochemistry.Results The positive expression rate of p53 and EGFR were statistically significant between the tissues of normal breast and breast invasive ductal carcinoma（P0.01）.p53 and EGFR protein expression were related to histological grade of breast invasive ductal carcinoma,clinical stage and lymph node metastasis.Conclusion p53 and EGFR play a certain role in the development of breast invasive ductal carcinoma.The experiment may provide a theoretical foundation for clinical therapy of breast invasive ductal carcinoma.
出处
《实用癌症杂志》
2013年第1期31-33,共3页
The Practical Journal of Cancer
